Andromeda Biotech Successfully Completes Patient Recruitment In Phase III Trials For Its Lead Drug, "DiaPep277" For Type 1 Diabetes

Andromeda Biotech Ltd. announces that it has completed patient recruitment in its' current Phase III study using DiaPep277 for the treatment of Type 1 diabetes. The current clinical study includes 456 patients and is being conducted at 40 medical centers in Europe, South Africa, and Israel.